Romi Lepetska advises on all aspects of EU, Dutch, and Belgian competition law.
She advises on a wide range of antitrust issues, including complex EU and international merger control proceedings, abuse of dominance cases, and restrictive practices. Her experience includes various sectors, notably pharmaceuticals, health care data, manufacturing and industrial services, and financial services. Romi co-authors an annual publication on developments in EU abuse of dominance.
Romi is a Dutch citizen. She joined the firm in 2012 and became an associate in 2013 in the Brussels office. From July 2015 to January 2016, Romi was seconded to the Benelux legal department of Philip Morris. She has been a resident in the London office since October 2017.
Prior to joining Cleary, Romi completed a blue book internship at the European Commission DG Competition.
Alstom before the European Commission and multiple other antitrust agencies globally in its proposed €15 billion combination with Siemens’ Mobility Business.
Allergan before the European Commission and multiple other antitrust agencies globally in connection with Allergan’s proposed $160 billion merger with Pfizer.
IMS Health on the global antitrust aspects of its acquisition of Cegedim and its merger of equals with Quintiles.
Citigroup in its EU investigations of alleged Yen Libor and Euribor rate manipulation.
Several clients in non-public cartel and antitrust investigations involving the European Commission and national competition authorities in the Netherlands and Belgium.
- Romano Subiotto QC, David R. Little, and Romi Lepetska, “The Application of Article 102 TFEU by the European Commission and the European Courts,” Journal of European Competition Law and Practice, 2015-2018